Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.59
MDCO's Cash to Debt is ranked higher than
64% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. MDCO: 1.59 )
MDCO' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.59

Equity to Asset 0.52
MDCO's Equity to Asset is ranked higher than
60% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. MDCO: 0.52 )
MDCO' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.89
Current: 0.52

0.51
0.89
Interest Coverage 0.85
MDCO's Interest Coverage is ranked lower than
58% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. MDCO: 0.85 )
MDCO' s 10-Year Interest Coverage Range
Min: 0.85   Max: 9999.99
Current: 0.85

0.85
9999.99
F-Score: 4
Z-Score: 1.86
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.92
MDCO's Operating margin (%) is ranked higher than
60% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. MDCO: 1.92 )
MDCO' s 10-Year Operating margin (%) Range
Min: -401.44   Max: 14.87
Current: 1.92

-401.44
14.87
Net-margin (%) 2.26
MDCO's Net-margin (%) is ranked higher than
61% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. MDCO: 2.26 )
MDCO' s 10-Year Net-margin (%) Range
Min: -385.2   Max: 29.79
Current: 2.26

-385.2
29.79
ROE (%) 1.74
MDCO's ROE (%) is ranked higher than
60% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MDCO: 1.74 )
MDCO' s 10-Year ROE (%) Range
Min: -102.97   Max: 29.26
Current: 1.74

-102.97
29.26
ROA (%) 0.89
MDCO's ROA (%) is ranked higher than
60% of the 748 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. MDCO: 0.89 )
MDCO' s 10-Year ROA (%) Range
Min: -434.4   Max: 22.07
Current: 0.89

-434.4
22.07
ROC (Joel Greenblatt) (%) 16.54
MDCO's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. MDCO: 16.54 )
MDCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8221.63   Max: 322.98
Current: 16.54

-8221.63
322.98
Revenue Growth (%) 10.10
MDCO's Revenue Growth (%) is ranked higher than
76% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. MDCO: 10.10 )
MDCO' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 88.9
Current: 10.1

0
88.9
EBITDA Growth (%) -7.90
MDCO's EBITDA Growth (%) is ranked higher than
59% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. MDCO: -7.90 )
MDCO' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -7.9
Current: -7.9

EPS Growth (%) -49.70
MDCO's EPS Growth (%) is ranked higher than
50% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. MDCO: -49.70 )
MDCO' s 10-Year EPS Growth (%) Range
Min: 0   Max: 27.6
Current: -49.7

0
27.6
» MDCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MDCO Guru Trades in Q3 2013

Vanguard Health Care Fund 4,250,415 sh (+219.22%)
George Soros 250,000 sh (+66.67%)
Chuck Royce 4,837,145 sh (+19.36%)
RS Investment Management Sold Out
Paul Tudor Jones 7,300 sh (-34.23%)
Steven Cohen 148,033 sh (-47.3%)
John Hussman 104,000 sh (-79.73%)
» More
Q4 2013

MDCO Guru Trades in Q4 2013

Joel Greenblatt 13,990 sh (New)
Vanguard Health Care Fund 4,599,069 sh (+8.2%)
John Hussman 104,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 4,599,842 sh (-4.91%)
George Soros 50,000 sh (-80%)
» More
Q1 2014

MDCO Guru Trades in Q1 2014

Jim Simons 53,042 sh (New)
RS Investment Management 523,764 sh (New)
Chuck Royce 6,115,200 sh (+32.94%)
Vanguard Health Care Fund 4,700,058 sh (+2.2%)
Joel Greenblatt Sold Out
George Soros Sold Out
John Hussman 67,000 sh (-35.58%)
» More
Q2 2014

MDCO Guru Trades in Q2 2014

Vanguard Health Care Fund 4,700,058 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MDCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-03-31 Reduce -35.58%0.1%$27.9 - $40.39 $ 24.09-28%67000
George Soros 2014-03-31 Sold Out 0.02%$27.9 - $40.39 $ 24.09-28%0
Joel Greenblatt 2014-03-31 Sold Out 0.01%$27.9 - $40.39 $ 24.09-28%0
George Soros 2013-12-31 Reduce -80%0.07%$31.48 - $38.91 $ 24.09-33%50000
Joel Greenblatt 2013-12-31 New Buy0.01%$31.48 - $38.91 $ 24.09-33%13990
John Hussman 2013-09-30 Reduce -79.73%0.57%$29.68 - $34.54 $ 24.09-24%104000
Vanguard Health Care Fund 2013-09-30 Add 219.22%0.33%$29.68 - $34.54 $ 24.09-24%4250415
George Soros 2013-09-30 Add 66.67%0.04%$29.68 - $34.54 $ 24.09-24%250000
John Hussman 2013-06-30 Reduce -26.29%0.22%$30.76 - $37.1 $ 24.09-28%513000
Vanguard Health Care Fund 2013-06-30 Add 181.56%0.1%$30.76 - $37.1 $ 24.09-28%1331500
George Soros 2013-06-30 Add 57.89%0.02%$30.76 - $37.1 $ 24.09-28%150000
John Burbank 2013-03-31 Sold Out 0.09%$23.97 - $33.41 $ 24.09-21%0
Vanguard Health Care Fund 2013-03-31 New Buy0.06%$23.97 - $33.41 $ 24.09-21%472900
George Soros 2013-03-31 New Buy0.04%$23.97 - $33.41 $ 24.09-21%95000
John Burbank 2012-12-31 New Buy0.09%$20.34 - $26.64 $ 24.096%100000
John Hussman 2012-09-30 New Buy0.38%$22.88 - $26.68 $ 24.09-4%615000
Joel Greenblatt 2012-09-30 Sold Out 0.03%$22.88 - $26.68 $ 24.09-4%0
Joel Greenblatt 2012-06-30 Reduce -79.52%0.11%$19.56 - $22.98 $ 24.0913%16302
George Soros 2012-06-30 Sold Out 0.07%$19.56 - $22.98 $ 24.0913%0
George Soros 2012-03-31 Reduce -80%0.8%$18.22 - $22.28 $ 24.0926%250000
George Soros 2011-12-31 Reduce -26.47%0.11%$16.6 - $20 $ 24.0930%1250000
George Soros 2011-09-30 New Buy0.43%$12.52 - $17 $ 24.0961%1700000
Joel Greenblatt 2011-09-30 Add 57.05%0.06%$12.52 - $17 $ 24.0961%73521
Joel Greenblatt 2011-06-30 Reduce -24.26%0.07%$15.36 - $19.11 $ 24.0944%46815
Charles Brandes 2011-06-30 Sold Out $15.36 - $19.11 $ 24.0944%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 67.10
MDCO's P/E(ttm) is ranked higher than
68% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. MDCO: 67.10 )
MDCO' s 10-Year P/E(ttm) Range
Min: 4.53   Max: 697.27
Current: 67.1

4.53
697.27
P/B 1.70
MDCO's P/B is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. MDCO: 1.70 )
MDCO' s 10-Year P/B Range
Min: 1.14   Max: 11.31
Current: 1.7

1.14
11.31
P/S 2.21
MDCO's P/S is ranked higher than
78% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. MDCO: 2.21 )
MDCO' s 10-Year P/S Range
Min: 0.9   Max: 18.4
Current: 2.21

0.9
18.4
PFCF 13.10
MDCO's PFCF is ranked higher than
95% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MDCO: 13.10 )
MDCO' s 10-Year PFCF Range
Min: 6.54   Max: 305.88
Current: 13.1

6.54
305.88
EV-to-EBIT 27.64
MDCO's EV-to-EBIT is ranked higher than
76% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.81 vs. MDCO: 27.64 )
MDCO' s 10-Year EV-to-EBIT Range
Min: 6.6   Max: 790.2
Current: 27.64

6.6
790.2
Shiller P/E 38.00
MDCO's Shiller P/E is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MDCO: 38.00 )
MDCO' s 10-Year Shiller P/E Range
Min: 25.91   Max: 748.5
Current: 38

25.91
748.5
Current Ratio 3.80
MDCO's Current Ratio is ranked higher than
82% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. MDCO: 3.80 )
MDCO' s 10-Year Current Ratio Range
Min: 0.75   Max: 10.09
Current: 3.8

0.75
10.09
Quick Ratio 3.25
MDCO's Quick Ratio is ranked higher than
82% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MDCO: 3.25 )
MDCO' s 10-Year Quick Ratio Range
Min: 0.75   Max: 9.44
Current: 3.25

0.75
9.44

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.30
MDCO's Price/DCF (Projected) is ranked higher than
94% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MDCO: 1.30 )
MDCO' s 10-Year Price/DCF (Projected) Range
Min: 0.84   Max: 11.15
Current: 1.3

0.84
11.15
Price/Median PS Value 0.70
MDCO's Price/Median PS Value is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. MDCO: 0.70 )
MDCO' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 58.55
Current: 0.7

0.31
58.55
Earnings Yield (Greenblatt) 3.60
MDCO's Earnings Yield (Greenblatt) is ranked higher than
64% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. MDCO: 3.60 )
MDCO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 15.2
Current: 3.6

0.1
15.2
Forward Rate of Return (Yacktman) 1.87
MDCO's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. MDCO: 1.87 )
MDCO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.1   Max: 3.7
Current: 1.87

-6.1
3.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MZN.Germany
Medicines was incorporated in Delaware on July 31, 1996. It is a global biopharmaceutical company focused on saving lives, alleviating suffering and improving the economic efficiency of the world's hospitals. It has four marketed products, Angiomax(bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a topical human recombinant thrombin. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. It also has a pipeline of acute and intensive care hospital products in development, including four late-stage development product candidates, cangrelor, oritavancin, MDCO-157 and IONSYS TM (fentanyl iontophoretic transdermal system), and early stage development product candidates, MDCO-216 and ALN-PCS02 and ALN-PCSsc of its ALN-PCS program. In addition to these products and product candidates, it has a portfolio of ten generic drugs. The Company also co-promotes the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States, as part of its global collaboration agreement with AstraZeneca LP, or AstraZeneca. Angiomax, Recothrom, Cleviprex, ready-to-use Argatroban and its products in development, their stage of development, their mechanism of action and the indications for which they have been approved for use or which they are intended to address. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.
» More Articles for MDCO

Headlines

Articles On GuruFocus.com
Chuck Royce Buys Stifel Financial, Tidewater, Alamos, Sells Kennametal, Gardner Denver, Gartner Apr 25 2013 
Weekly CFO Sells Highlight: BK, MDCO, EBAY, MS, PHMD Jan 27 2013 
Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS Jan 21 2013 
George Soros' Top Buys in the Last Quarter Dec 23 2011 
George Soros Buys Amazon.com Inc., Motorola Solutions, Sandisk, Sells Ralph Lauren, Dendreon, Lawson Nov 15 2011 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 100,000 Shares Mar 01 2011 
Medicines Company Reports Operating Results (10-Q) Nov 09 2010 
Medicines Company Reports Operating Results (10-Q) May 10 2010 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 181,500 Shares May 04 2010 
Medicines Company Reports Operating Results (10-Q) Nov 09 2009 


More From Other Websites
The Medicines Co.'s (MDCO) Q2 Earnings Decline Y/Y Jul 24 2014
Medicines (MDCO) is Oversold: Can It Recover? Jul 24 2014
The Medicines Company Reports Second Quarter and First Half 2014 Results Jul 23 2014
Medicines Co Earnings Call scheduled for 8:30 am ET today Jul 23 2014
MEDICINES CO /DE Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 23 2014
Q2 2014 The Medicines Company Earnings Release - Before Market Open Jul 23 2014
The Medicines Company Reports Second Quarter and First Half 2014 Results Jul 23 2014
The Medicines Company to Announce Second Quarter and First Half 2014 Financial Results on Wednesday,... Jul 09 2014
The Medicines Company to Announce Second Quarter and First Half 2014 Financial Results on Wednesday,... Jul 09 2014
The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the... Jul 07 2014
The Medicines Co. receives market authorization renweal for Angiox Jul 07 2014
The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the... Jul 07 2014
Hyperion's Ravicti Submission Accepted in EU Jun 26 2014
ORBACTIVTM (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine Jun 05 2014
The Medicines Company to Participate in Goldman Sachs 35th Annual Global Healthcare Conference Jun 04 2014
The Medicines Company Presents Seven Hospital Data Analyses at Leading Health Economics and Outcomes... Jun 04 2014
MEDICINES CO /DE Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 30 2014
The Medicines Company to Participate in 2014 Jefferies Global Healthcare Conference May 27 2014
Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published... May 22 2014
The Medicines Co. to host analyst and investor meeting May 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide